 CFF struck a similar agreement with the company, Altus Pharmaceuticals, to fund development of a recombinant enzyme that could treat pancreatic disease in people with cystic fibrosis.When Altus reported to CFF that it didn't have funds to continue developing the drug, CFF seized control of the asset and eventually licensed it to Alnara Pharmaceuticals, which developed the drug further and was acquired by Eli Lilly in 2010.UW-Madison Professor Emeritus Kenneth Zeichner wrote a paper criticizing the role of the New Schools Venture Fund in bringing deregulation and market-based practices into schools in the US.